CYP19A1 and breast cancer: Ribociclib (LEE011) is a highly selective, orally bioavailable CDK4/6 inhibitor that has recently been approved for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer in combination with an aromatase inhibitor [18, 19].